# Zepbound tops Wegovy for weight loss in first head-to-head study comparing the drugs - CBS News

## Metadata
| Field | Value |
|-------|-------|
| Source | CBS News |
| URL | https://news.google.com/rss/articles/CBMihgFBVV95cUxPTDk4MGd5cGJrNlhmMFVJT2pwSEhUalBXVjlsRk4xYkNxdXNkazdzOXJkaVpVWE9JeEo4X01GRF84YWZBd0Q0SmpwMGp0WXB2MlR6WDZHZ2pYR0k2SWxBZ3JVcWVFU24wYW41ZVgxSGVlMGlIYzlGT3EzeW93X2xvYVg4Y2pHZ9IBiwFBVV95cUxQS3o1RFg3Ri15TTNFQlhYQS1MZUFoX2ZkN1dwZ1BwS05lbFoyUEstTVQ1V2ZaSzdLVzhhb3hFZUFPT0JORGdfLVNQbnAtSlFQdEVjRGhweklHQ3ZfOEFXZU1mLXN1b1JRNUFNTTdWV3NpNGdjOUd4VTAwRFpiOXY2azRCMnJVV2dVd1dB?oc=5&hl=en-US&gl=US&ceid=US:en |
| Scraped | 2025-12-30 07:00 |
| Category | GLP-1 |
| Relevance | 9/10 |
| Signal | bull |

## Investment Summary
First head-to-head clinical study comparing GLP-1 weight loss drugs demonstrates superior efficacy of Zepbound (tirzepatide) over Wegovy, potentially signaling market disruption in obesity treatment.

## Key Entities
Eli Lilly, Novo Nordisk, Zepbound, Wegovy

## Dollar Amounts
None mentioned

---

## Article Content

*Full content could not be extracted. Visit URL for details.*

---

#healthcare-news #glp-1 #auto-scraped
